Larimar Therapeutics Key Executives
This section highlights Larimar Therapeutics's key executives, including their titles and compensation details.
Find Contacts at Larimar Therapeutics
(Showing 0 of )
Larimar Therapeutics Earnings
This section highlights Larimar Therapeutics's earnings, including key dates, EPS, earnings reports, and earnings call transcripts.
Next Earnings Date
Last Earnings Results
Earnings Call Transcripts
| Transcript | Quarter | Year | Date | Estimated EPS | Actual EPS |
|---|
Larimar Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing treatments for rare diseases using its novel cell penetrating peptide technology platform. Its lead product candidate is CTI-1601, which is in Phase 1 clinical trial for the treatment of Friedreich's ataxia, a rare, progressive, and fatal genetic disease. The company is based in Bala Cynwyd, Pennsylvania.
$2.14
Stock Price
$136.70M
Market Cap
65
Employees
Bala Cynwyd, PA
Location
Financial Statements
Access annual & quarterly financial statements for Larimar Therapeutics, including income statements, balance sheets, and cash flow statements..
Annual Income Statement
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $311.00K | $272.00K | $326.00K | $155.00K |
| Gross Profit | $- | $-311.00K | $-272.00K | $-326.00K | $-155.00K |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $73.28M | $27.36M | $24.25M | $38.40M | $31.41M |
| General and Administrative Expenses | $17.61M | $14.09M | $12.28M | $12.07M | $11.40M |
| Selling and Marketing Expenses | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $17.61M | $14.09M | $12.28M | $12.07M | $11.40M |
| Other Expenses | $- | $- | $1.17M | $-171.00K | $322.00K |
| Operating Expenses | $90.89M | $41.76M | $36.53M | $50.47M | $42.80M |
| Cost and Expenses | $- | $41.76M | $36.53M | $50.47M | $42.80M |
| Interest Income | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $- | $311.00K | $272.00K | $326.00K | $155.00K |
| EBITDA | $-90.89M | $-41.45M | $-35.08M | $-50.14M | $-42.65M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-90.89M | $-41.76M | $-36.53M | $-50.47M | $-42.80M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $10.29M | $4.81M | $1.17M | $-171.00K | $322.00K |
| Income Before Tax | $-80.60M | $-36.95M | $-35.35M | $-50.64M | $-42.48M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $-1.17M | $-326.00K | $-155.00K |
| Net Income | $-80.60M | $-36.95M | $-34.18M | $-50.31M | $-42.33M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-1.32 | $-0.84 | $-1.33 | $-2.93 | $-3.56 |
| EPS Diluted | $-1.32 | $-0.84 | $-1.33 | $-2.93 | $-3.56 |
| Weighted Average Shares Outstanding | 61.26M | 43.90M | 25.76M | 17.16M | 11.88M |
| Weighted Average Shares Outstanding Diluted | 61.26M | 43.90M | 25.76M | 17.16M | 11.88M |
| SEC Filing | Source | Source | Source | Source | Source |
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Cost of Revenue | $- | $74.00K | $87.00K | $80.00K | $81.00K | $69.00K | $49.00K | $54.00K | $32.00K | $77.00K | $81.00K | $82.00K | $88.00K | $88.00K | $77.00K | $73.00K | $- | $- | $- | $- |
| Gross Profit | $- | $-74.00K | $-87.00K | $-80.00K | $-81.00K | $-69.00K | $-49.00K | $-54.00K | $-32.00K | $-77.00K | $-81.00K | $-82.00K | $-88.00K | $-88.00K | $-77.00K | $-73.00K | $- | $- | $- | $- |
| Gross Profit Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Research and Development Expenses | $26.74M | $13.92M | $19.59M | $12.86M | $10.57M | $6.58M | $5.88M | $4.56M | $7.22M | $5.58M | $5.64M | $5.81M | $6.29M | $14.03M | $9.10M | $8.97M | $10.56M | $6.92M | $8.91M | $5.01M |
| General and Administrative Expenses | $4.55M | $4.34M | $4.92M | $3.79M | $3.51M | $3.75M | $3.75M | $3.08M | $3.22M | $2.93M | $3.04M | $3.08M | $2.79M | $2.70M | $3.44M | $3.13M | $3.83M | $3.42M | $2.49M | $1.67M |
| Selling and Marketing Expenses | $- | $- | $100.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Selling General and Administrative Expenses | $4.55M | $4.34M | $4.92M | $3.79M | $3.51M | $3.75M | $3.75M | $3.08M | $3.22M | $2.93M | $3.04M | $3.08M | $2.79M | $2.70M | $3.44M | $3.13M | $3.83M | $3.42M | $2.49M | $1.67M |
| Other Expenses | $- | $- | $2.97M | $2.08M | $1.17M | $1.27M | $1.25M | $1.11M | $1.01M | $193.00K | $20.00K | $-56.00K | $-48.00K | $-75.00K | $-66.00K | $18.00K | $192.00K | $61.00K | $69.00K | $- |
| Operating Expenses | $31.29M | $18.26M | $24.51M | $16.65M | $14.08M | $10.34M | $9.62M | $7.64M | $10.44M | $8.51M | $8.69M | $8.89M | $9.09M | $16.73M | $12.54M | $12.11M | $14.39M | $10.34M | $11.40M | $6.67M |
| Cost and Expenses | $31.29M | $18.26M | $24.60M | $16.73M | $14.16M | $10.34M | $9.62M | $7.64M | $10.44M | $8.51M | $8.69M | $8.89M | $9.09M | $16.73M | $12.54M | $12.11M | $14.39M | $10.34M | $11.40M | $6.67M |
| Interest Income | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Interest Expense | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $56.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Depreciation and Amortization | $77.00K | $74.00K | $87.00K | $80.00K | $81.00K | $69.00K | $49.00K | $78.00K | $32.00K | $77.00K | $81.00K | $82.00K | $88.00K | $88.00K | $77.00K | $73.00K | $50.00K | $50.00K | $32.00K | $23.00K |
| EBITDA | $-31.22M | $-18.26M | $-24.51M | $-16.65M | $-14.08M | $-10.26M | $-9.54M | $-7.56M | $-10.36M | $-8.44M | $-8.61M | $-8.80M | $-9.00M | $-16.64M | $-12.47M | $-12.03M | $-14.35M | $-10.29M | $-11.37M | $-6.65M |
| EBITDA Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Operating Income | $-31.29M | $-18.26M | $-24.60M | $-16.73M | $-14.16M | $-10.34M | $-9.62M | $-7.64M | $-10.44M | $-8.51M | $-8.69M | $-8.89M | $-9.09M | $-16.73M | $-12.54M | $-12.11M | $-14.39M | $-10.34M | $-11.40M | $-6.67M |
| Operating Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Total Other Income Expenses Net | $2.47M | $2.77M | $2.97M | $2.08M | $1.17M | $1.27M | $1.25M | $1.11M | $1.01M | $193.00K | $20.00K | $-56.00K | $-48.00K | $-75.00K | $-66.00K | $18.00K | $192.00K | $61.00K | $69.00K | $- |
| Income Before Tax | $-28.82M | $-15.50M | $-21.63M | $-14.65M | $-12.99M | $-9.06M | $-8.37M | $-6.53M | $-9.43M | $-8.32M | $-8.67M | $-8.94M | $-9.13M | $-16.80M | $-12.61M | $-12.09M | $-14.20M | $-10.27M | $-11.33M | $-6.67M |
| Income Before Tax Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Income Tax Expense | $- | $- | $- | $36.72K | $37.19K | $-76.00K | $-46.09K | $-1.11M | $-1.01M | $-193.00K | $-20.00K | $56.00K | $-88.00K | $- | $- | $- | $-50.00K | $-50.00K | $-32.00K | $-35.00K |
| Net Income | $-28.82M | $-15.50M | $-21.63M | $-14.65M | $-12.99M | $-9.06M | $-8.37M | $-5.42M | $-8.41M | $-8.13M | $-8.65M | $-9.00M | $-9.13M | $-16.80M | $-12.61M | $-12.09M | $-14.20M | $-10.27M | $-11.33M | $-6.67M |
| Net Income Ratio | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| EPS | $-0.47 | $-0.24 | $-0.34 | $-0.27 | $-0.30 | $-0.21 | $-0.19 | $-0.12 | $-0.35 | $-0.37 | $-0.47 | $-0.49 | $-0.50 | $-0.92 | $-0.79 | $-0.76 | $-0.89 | $-0.64 | $-1.21 | $-0.72 |
| EPS Diluted | $-0.47 | $-0.24 | $-0.34 | $-0.27 | $-0.30 | $-0.21 | $-0.19 | $-0.12 | $-0.35 | $-0.37 | $-0.47 | $-0.49 | $-0.50 | $-0.92 | $-0.79 | $-0.76 | $-0.89 | $-0.64 | $-1.21 | $-0.72 |
| Weighted Average Shares Outstanding | 61.26M | 63.81M | 63.80M | 53.55M | 43.91M | 43.90M | 43.90M | 43.90M | 23.99M | 22.23M | 18.34M | 18.34M | 18.34M | 18.29M | 16.00M | 16.00M | 15.99M | 15.98M | 9.38M | 9.21M |
| Weighted Average Shares Outstanding Diluted | 61.26M | 63.81M | 63.80M | 53.55M | 43.91M | 43.90M | 43.90M | 43.90M | 23.99M | 22.23M | 18.34M | 18.34M | 18.34M | 18.29M | 16.00M | 16.00M | 15.99M | 15.98M | 9.38M | 9.21M |
| SEC Filing | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source | Source |
Annual Balance Sheet
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Cash and Cash Equivalents | $33.22M | $26.75M | $26.82M | $70.10M | $68.15M |
| Short Term Investments | $150.24M | $60.04M | $91.60M | $- | $24.49M |
| Cash and Short Term Investments | $183.45M | $86.79M | $118.43M | $70.10M | $92.64M |
| Net Receivables | $- | $- | $- | $208.00K | $32.00K |
| Inventory | $- | $- | $- | $-208.00K | $-32.00K |
| Other Current Assets | $11.85M | $3.38M | $2.31M | $1.90M | $5.28M |
| Total Current Assets | $195.30M | $90.17M | $120.74M | $72.20M | $97.95M |
| Property Plant Equipment Net | $3.72M | $3.76M | $3.69M | $4.46M | $4.98M |
| Goodwill | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $1.34M | $1.34M | $1.34M | $1.34M |
| Tax Assets | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.20M | $659.00K | $638.00K | $669.00K | $419.00K |
| Total Non-Current Assets | $4.92M | $5.76M | $5.67M | $6.46M | $6.73M |
| Other Assets | $- | $- | $- | $-0 | $-0 |
| Total Assets | $200.22M | $95.94M | $126.41M | $78.67M | $104.69M |
| Account Payables | $2.42M | $1.28M | $1.69M | $1.66M | $2.63M |
| Short Term Debt | $1.06M | $837.00K | $1.22M | $1.19M | $1.03M |
| Tax Payables | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- |
| Other Current Liabilities | $20.87M | $7.39M | $7.80M | $6.00M | $5.33M |
| Total Current Liabilities | $24.36M | $9.51M | $10.71M | $8.85M | $8.99M |
| Long Term Debt | $4.06M | $4.71M | $4.80M | $5.41M | $6.00M |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $4.06M | $4.71M | $4.80M | $5.41M | $6.00M |
| Other Liabilities | $- | $- | $- | $- | $- |
| Total Liabilities | $28.41M | $14.21M | $15.50M | $14.25M | $14.99M |
| Preferred Stock | $- | $- | $- | $- | $- |
| Common Stock | $64.00K | $43.00K | $43.00K | $18.00K | $15.00K |
| Retained Earnings | $-269.16M | $-188.55M | $-151.60M | $-116.25M | $-65.61M |
| Accumulated Other Comprehensive Income Loss | $- | $81.00K | $-31.00K | $-0 | $1.00K |
| Other Total Stockholders Equity | $440.91M | $270.15M | $262.50M | $180.65M | $155.29M |
| Total Stockholders Equity | $171.81M | $81.72M | $110.90M | $64.41M | $89.69M |
| Total Equity | $171.81M | $81.72M | $110.90M | $64.41M | $89.69M |
| Total Liabilities and Stockholders Equity | $200.22M | $95.94M | $126.41M | $78.67M | $104.69M |
| Minority Interest | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $200.22M | $95.94M | $126.41M | $78.67M | $104.69M |
| Total Investments | $150.24M | $61.38M | $91.60M | $1.34M | $24.49M |
| Total Debt | $5.12M | $5.55M | $5.41M | $6.00M | $6.52M |
| Net Debt | $-28.10M | $-21.20M | $-21.42M | $-64.09M | $-61.63M |
Balance Sheet Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and Cash Equivalents | $33.22M | $35.07M | $32.31M | $110.12M | $26.75M | $38.72M | $94.32M | $111.52M | $26.82M | $86.05M | $19.74M | $62.56M | $70.10M | $71.53M | $70.63M | $62.19M | $68.15M | $101.31M | $112.67M | $887.00K |
| Short Term Investments | $150.24M | $168.64M | $193.75M | $117.17M | $60.04M | $56.87M | $9.88M | $- | $91.60M | $38.65M | $35.19M | $- | $- | $6.50M | $- | $19.25M | $24.49M | $1.00M | $1.01M | $24.91M |
| Cash and Short Term Investments | $183.45M | $203.71M | $226.06M | $227.30M | $86.79M | $95.59M | $104.20M | $111.52M | $118.43M | $124.70M | $54.92M | $62.56M | $70.10M | $78.02M | $70.63M | $81.44M | $92.64M | $102.31M | $113.68M | $887.00K |
| Net Receivables | $1.05M | $943.00K | $751.00K | $1.08M | $- | $- | $- | $- | $- | $114.00K | $237.00K | $323.00K | $208.00K | $219.00K | $67.00K | $- | $32.00K | $34.00K | $55.00K | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $-300.00K | $-300.00K | $- | $- | $- | $- | $-208.00K | $- | $- | $- | $-32.00K | $-34.00K | $-55.00K | $-214.00K |
| Other Current Assets | $10.80M | $8.61M | $4.32M | $2.58M | $3.38M | $2.89M | $2.28M | $1.94M | $2.31M | $2.31M | $1.58M | $1.99M | $1.90M | $3.01M | $3.34M | $4.69M | $5.28M | $5.47M | $5.37M | $5.12M |
| Total Current Assets | $195.30M | $213.26M | $231.13M | $230.95M | $90.17M | $98.48M | $106.48M | $113.46M | $120.74M | $127.13M | $56.74M | $64.88M | $72.20M | $81.25M | $74.04M | $86.13M | $97.95M | $107.82M | $119.11M | $6.00M |
| Property Plant Equipment Net | $3.72M | $3.81M | $4.06M | $3.52M | $3.76M | $3.50M | $3.25M | $3.47M | $3.69M | $3.91M | $4.12M | $4.34M | $4.46M | $4.67M | $4.88M | $4.80M | $4.98M | $4.72M | $4.93M | $842.00K |
| Goodwill | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Goodwill and Intangible Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Long Term Investments | $- | $- | $1.34M | $13.05M | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M | $1.34M | $- | $- | $- | $- |
| Tax Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Assets | $1.20M | $1.96M | $636.00K | $678.00K | $659.00K | $634.00K | $644.00K | $632.00K | $638.00K | $643.00K | $649.00K | $668.00K | $669.00K | $671.00K | $672.00K | $750.00K | $1.76M | $1.42M | $1.42M | $147.00K |
| Total Non-Current Assets | $4.92M | $5.76M | $6.03M | $17.25M | $5.76M | $5.47M | $5.24M | $5.44M | $5.67M | $5.89M | $6.11M | $6.34M | $6.46M | $6.68M | $6.89M | $6.89M | $6.73M | $6.14M | $6.35M | $989.00K |
| Other Assets | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-0 | $- | $- | $-0 | $-0 | $0 | $0 | $- |
| Total Assets | $200.22M | $219.02M | $237.16M | $248.21M | $95.94M | $103.95M | $111.72M | $118.91M | $126.41M | $133.01M | $62.85M | $71.22M | $78.67M | $87.94M | $80.93M | $93.02M | $104.69M | $113.96M | $125.46M | $6.99M |
| Account Payables | $2.42M | $1.69M | $2.92M | $1.92M | $1.28M | $756.00K | $2.34M | $695.00K | $1.69M | $849.00K | $425.00K | $2.42M | $1.66M | $1.77M | $1.46M | $3.23M | $2.63M | $1.27M | $2.26M | $322.00K |
| Short Term Debt | $1.06M | $2.05M | $1.98M | $825.00K | $837.00K | $1.42M | $1.13M | $1.18M | $611.00K | $1.26M | $1.28M | $1.23M | $594.00K | $1.15M | $1.11M | $1.07M | $515.00K | $1.05M | $1.18M | $7.89M |
| Tax Payables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Revenue | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-7.68M |
| Other Current Liabilities | $20.87M | $12.55M | $16.25M | $10.10M | $7.39M | $4.39M | $3.80M | $6.14M | $8.41M | $7.31M | $6.02M | $5.22M | $6.59M | $7.39M | $5.12M | $4.08M | $5.84M | $2.86M | $3.21M | $1.65M |
| Total Current Liabilities | $24.36M | $16.29M | $21.16M | $12.84M | $9.51M | $6.56M | $7.28M | $8.01M | $10.71M | $9.42M | $7.72M | $8.87M | $8.85M | $10.31M | $7.69M | $8.38M | $8.99M | $5.18M | $6.64M | $4.39M |
| Long Term Debt | $4.06M | $4.34M | $4.60M | $4.52M | $4.71M | $4.68M | $4.51M | $4.66M | $4.80M | $4.93M | $5.08M | $5.25M | $5.41M | $5.57M | $5.71M | $5.86M | $6.00M | $6.14M | $6.27M | $341.00K |
| Deferred Revenue Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Deferred Tax Liabilities Non-Current | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Non-Current Liabilities | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Non-Current Liabilities | $4.06M | $4.34M | $4.60M | $4.52M | $4.71M | $4.68M | $4.51M | $4.66M | $4.80M | $4.93M | $5.08M | $5.25M | $5.41M | $5.57M | $5.71M | $5.86M | $6.00M | $6.14M | $6.27M | $341.00K |
| Other Liabilities | $- | $- | $1 | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities | $28.41M | $20.62M | $25.76M | $17.36M | $14.21M | $11.24M | $11.79M | $12.67M | $15.50M | $14.35M | $12.80M | $14.12M | $14.25M | $15.87M | $13.41M | $14.23M | $14.99M | $11.32M | $12.91M | $4.74M |
| Preferred Stock | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock | $64.00K | $64.00K | $64.00K | $64.00K | $43.00K | $43.00K | $43.00K | $43.00K | $43.00K | $43.00K | $18.00K | $18.00K | $18.00K | $18.00K | $15.00K | $15.00K | $15.00K | $15.00K | $15.00K | $1.00K |
| Retained Earnings | $-269.16M | $-240.33M | $-224.84M | $-203.21M | $-188.55M | $-175.56M | $-166.50M | $-158.13M | $-151.60M | $-142.18M | $-133.86M | $-125.19M | $-116.25M | $-107.12M | $-90.31M | $-77.70M | $-65.61M | $-51.41M | $-41.14M | $-29.81M |
| Accumulated Other Comprehensive Income Loss | $148.00K | $358.00K | $-150.00K | $-25.00K | $81.00K | $7.00K | $12.00K | $-0 | $-31.00K | $-40.00K | $-57.00K | $-0 | $-0 | $- | $1.00K | $1.00K | $1.00K | $-2.00K | $-3.00K | $62.00K |
| Other Total Stockholders Equity | $440.76M | $438.31M | $436.32M | $434.01M | $270.15M | $268.22M | $266.37M | $264.33M | $262.50M | $260.84M | $183.96M | $182.28M | $180.65M | $179.16M | $157.82M | $156.47M | $155.29M | $154.04M | $153.67M | $402.20M |
| Total Stockholders Equity | $171.81M | $198.40M | $211.40M | $230.84M | $81.72M | $92.71M | $99.93M | $106.24M | $110.90M | $118.66M | $50.06M | $57.10M | $64.41M | $72.07M | $67.53M | $78.78M | $89.69M | $102.64M | $112.54M | $2.26M |
| Total Equity | $171.81M | $198.40M | $211.40M | $230.84M | $81.72M | $92.71M | $99.93M | $106.24M | $110.90M | $118.66M | $50.06M | $57.10M | $64.41M | $72.07M | $67.53M | $78.78M | $89.69M | $102.64M | $112.54M | $2.26M |
| Total Liabilities and Stockholders Equity | $200.22M | $219.02M | $237.16M | $248.21M | $95.94M | $103.95M | $111.72M | $118.91M | $126.41M | $133.01M | $62.85M | $71.22M | $78.67M | $87.94M | $80.93M | $93.02M | $104.69M | $113.96M | $125.46M | $6.99M |
| Minority Interest | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Total Liabilities and Total Equity | $200.22M | $219.02M | $237.16M | $248.21M | $95.94M | $103.95M | $111.72M | $118.91M | $126.41M | $133.01M | $62.85M | $71.22M | $78.67M | $87.94M | $80.93M | $93.02M | $104.69M | $113.96M | $125.46M | $6.99M |
| Total Investments | $150.24M | $168.64M | $195.09M | $130.22M | $61.38M | $56.87M | $9.88M | $1.34M | $91.60M | $38.65M | $35.19M | $1.34M | $1.34M | $6.50M | $1.34M | $19.25M | $24.49M | $1.00M | $1.01M | $24.91M |
| Total Debt | $5.12M | $5.36M | $5.59M | $5.34M | $5.55M | $5.39M | $5.08M | $5.25M | $5.41M | $5.57M | $5.71M | $5.86M | $6.00M | $6.14M | $6.27M | $6.39M | $6.52M | $6.66M | $6.86M | $341.00K |
| Net Debt | $-28.10M | $-29.70M | $-26.72M | $-104.78M | $-21.20M | $-33.33M | $-89.24M | $-106.28M | $-21.42M | $-80.48M | $-14.02M | $-56.70M | $-64.09M | $-65.39M | $-64.36M | $-55.80M | $-61.63M | $-94.64M | $-105.81M | $-546.00K |
Annual Cash Flow
| Breakdown | December 31, 2024 | December 31, 2023 | December 31, 2022 | December 31, 2021 | December 31, 2020 |
|---|---|---|---|---|---|
| Net Income | $-80.60M | $-36.95M | $-35.35M | $-50.64M | $-42.48M |
| Depreciation and Amortization | $318.00K | $311.00K | $318.00K | $326.00K | $155.00K |
| Deferred Income Tax | $- | $- | $- | $- | $- |
| Stock Based Compensation | $8.80M | $7.62M | $6.62M | $5.47M | $2.16M |
| Change in Working Capital | $6.17M | $-2.51M | $1.67M | $2.75M | $-2.04M |
| Accounts Receivables | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- |
| Accounts Payables | $1.14M | $-403.00K | $26.00K | $-974.00K | $-3.29M |
| Other Working Capital | $5.03M | $-2.11M | $1.64M | $3.72M | $1.25M |
| Other Non Cash Items | $-5.45M | $-1.93M | $-820.00K | $-15.00K | $10.00K |
| Net Cash Provided by Operating Activities | $-70.76M | $-33.46M | $-27.57M | $-42.10M | $-42.20M |
| Investments in Property Plant and Equipment | $-515.00K | $-164.00K | $-100.00K | $-333.00K | $-62.00K |
| Acquisitions Net | $- | $-33.52K | $90.86K | $-24.50K | $-1.30M |
| Purchases of Investments | $-227.87M | $-101.23M | $-133.61M | $-8.25M | $-24.49M |
| Sales Maturities of Investments | $143.00M | $134.75M | $42.75M | $32.75M | $1.00M |
| Other Investing Activities | $- | $33.52K | $-90.86K | $24.50K | $41.93M |
| Net Cash Used for Investing Activities | $-85.39M | $33.35M | $-90.96M | $24.17M | $17.09M |
| Debt Repayment | $- | $- | $- | $- | $- |
| Common Stock Issued | $161.81M | $30.00K | $75.26M | $19.89M | $75.59M |
| Common Stock Repurchased | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- |
| Other Financing Activities | $77.00K | $30.00K | $- | $- | $18.00M |
| Net Cash Used Provided by Financing Activities | $161.88M | $30.00K | $75.26M | $19.89M | $93.59M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- |
| Net Change in Cash | $5.74M | $-76.00K | $-43.27M | $1.95M | $68.48M |
| Cash at End of Period | $33.82M | $26.75M | $28.16M | $71.44M | $69.49M |
| Cash at Beginning of Period | $28.09M | $26.82M | $71.44M | $69.49M | $1.01M |
| Operating Cash Flow | $-70.76M | $-33.46M | $-27.57M | $-42.10M | $-42.20M |
| Capital Expenditure | $-515.00K | $-164.00K | $-100.00K | $-333.00K | $-62.00K |
| Free Cash Flow | $-71.28M | $-33.62M | $-27.67M | $-42.44M | $-42.26M |
Cash Flow Charts
| Breakdown | December 31, 2024 | September 30, 2024 | June 30, 2024 | March 31, 2024 | December 31, 2023 | September 30, 2023 | June 30, 2023 | March 31, 2023 | December 31, 2022 | September 30, 2022 | June 30, 2022 | March 31, 2022 | December 31, 2021 | September 30, 2021 | June 30, 2021 | March 31, 2021 | December 31, 2020 | September 30, 2020 | June 30, 2020 | March 31, 2020 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Income | $-28.82M | $-15.50M | $-21.63M | $-14.65M | $-12.99M | $-9.06M | $-8.37M | $-6.53M | $-9.43M | $-8.32M | $-8.67M | $-8.94M | $-9.13M | $-16.80M | $-12.61M | $-12.09M | $-14.20M | $-10.27M | $-11.33M | $-6.67M |
| Depreciation and Amortization | $77.00K | $74.00K | $87.00K | $80.00K | $81.00K | $76.00K | $76.00K | $78.00K | $78.00K | $77.00K | $81.00K | $82.00K | $88.00K | $88.00K | $77.00K | $73.00K | $50.00K | $50.00K | $32.00K | $23.00K |
| Deferred Income Tax | $- | $- | $- | $- | $-1.55M | $-565.00K | $-29.00K | $- | $- | $- | $- | $5.00K | $- | $- | $- | $- | $- | $- | $- | $- |
| Stock Based Compensation | $2.41M | $1.96M | $2.30M | $2.13M | $1.92M | $1.82M | $2.04M | $1.83M | $1.64M | $1.67M | $1.68M | $1.64M | $1.48M | $1.46M | $1.35M | $1.18M | $1.01M | $370.00K | $752.00K | $29.00K |
| Change in Working Capital | $5.76M | $-9.32M | $7.07M | $2.66M | $2.31M | $-1.46M | $-1.06M | $-2.30M | $1.79M | $762.00K | $-572.00K | $-307.00K | $-350.00K | $3.06M | $401.00K | $-366.00K | $3.29M | $-1.38M | $-1.65M | $-2.30M |
| Accounts Receivables | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Inventory | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Accounts Payables | $738.00K | $-1.22M | $1.34M | $290.00K | $527.00K | $-1.59M | $1.65M | $-991.00K | $917.00K | $344.00K | $-1.89M | $657.00K | $-97.00K | $589.00K | $-2.03M | $564.00K | $905.00K | $-909.00K | $-760.00K | $-2.52M |
| Other Working Capital | $5.02M | $-8.10M | $5.74M | $2.37M | $1.78M | $127.00K | $-2.71M | $991.00K | $869.00K | $418.00K | $1.32M | $-964.00K | $-253.00K | $2.47M | $2.43M | $-930.00K | $2.38M | $-470.00K | $-893.00K | $225.00K |
| Other Non Cash Items | $-1.24M | $-1.76M | $-682.00K | $1.37M | $896.00K | $-7.00K | $-27.00K | $-640.00K | $-754.00K | $-63.00K | $-3.00K | $-5.00K | $-2.00K | $-7.00K | $-1.00K | $-5.00K | $-1.00K | $11.00K | $-760 | $-2.52K |
| Net Cash Provided by Operating Activities | $-21.82M | $-24.55M | $-13.99M | $-10.41M | $-9.34M | $-9.20M | $-7.37M | $-7.55M | $-6.67M | $-5.88M | $-7.49M | $-7.53M | $-7.92M | $-12.20M | $-10.78M | $-11.21M | $-9.86M | $-11.22M | $-12.20M | $-8.92M |
| Investments in Property Plant and Equipment | $-179.00K | $-62.00K | $-274.00K | $- | $-164.00K | $- | $- | $- | $- | $- | $-100.00K | $- | $-9.00K | $-293.00K | $-31.00K | $- | $-1.00K | $-5.00K | $- | $-58.00K |
| Acquisitions Net | $- | $- | $- | $- | $2.46K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $-60.00K | $-3.00K | $-513.00K | $-720.00K |
| Purchases of Investments | $-38.62M | $-22.67M | $-81.72M | $-84.86M | $-34.97M | $-56.42M | $-9.85M | $- | $-71.98M | $-26.38M | $-35.24M | $- | $-1.00K | $-6.50M | $- | $-1.75M | $-24.49M | $- | $- | $-2.34M |
| Sales Maturities of Investments | $58.00M | $50.00M | $18.50M | $16.50M | $32.50M | $9.99M | $9.00K | $92.25M | $19.75M | $23.00M | $- | $- | $6.50M | $- | $19.25M | $7.00M | $1.00M | $- | $- | $20.53M |
| Other Investing Activities | $- | $- | $-63.22M | $-68.36M | $-2.46K | $-46.43K | $-9.84K | $92.25K | $-52.23K | $-3.38K | $-35.24K | $- | $6.50K | $-6.50K | $19.25K | $5.25K | $2.00K | $- | $41.93M | $-18.19M |
| Net Cash Used for Investing Activities | $19.20M | $27.27M | $-63.49M | $-68.36M | $-2.63M | $-46.43M | $-9.84M | $92.25M | $-52.23M | $-3.38M | $-35.34M | $- | $6.49M | $-6.79M | $19.22M | $5.25M | $-23.55M | $-8.00K | $41.42M | $-778.00K |
| Debt Repayment | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Common Stock Issued | $- | $-161.82M | $- | $162.15M | $- | $30.00K | $- | $- | $-316.00K | $75.57M | $- | $- | $- | $19.89M | $- | $- | $242.00K | $-135.00K | $- | $- |
| Common Stock Repurchased | $- | $334.00K | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Dividends Paid | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Other Financing Activities | $36.00K | $30.00K | $11.00K | $- | $- | $30.00K | $- | $- | $- | $75.57M | $- | $- | $- | $- | $- | $- | $- | $- | $83.90M | $9.58M |
| Net Cash Used Provided by Financing Activities | $36.00K | $30.00K | $-334.00K | $162.15M | $- | $30.00K | $- | $- | $-316.00K | $75.57M | $- | $- | $- | $19.89M | $- | $- | $242.00K | $-135.00K | $83.90M | $9.58M |
| Effect of Forex Changes on Cash | $- | $- | $- | $- | $- | $55.54M | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- | $- |
| Net Change in Cash | $-2.58M | $4.09M | $-77.81M | $83.38M | $-11.97M | $-55.60M | $-17.20M | $84.70M | $-59.22M | $66.31M | $-42.83M | $-7.53M | $-1.43M | $895.00K | $8.44M | $-5.96M | $-33.16M | $-11.37M | $113.12M | $-122.00K |
| Cash at End of Period | $33.82M | $36.41M | $32.31M | $110.12M | $26.75M | $40.06M | $95.66M | $112.86M | $28.16M | $87.39M | $21.07M | $63.90M | $71.44M | $72.86M | $71.97M | $63.53M | $69.49M | $102.65M | $114.01M | $887.00K |
| Cash at Beginning of Period | $36.41M | $32.31M | $110.12M | $26.75M | $38.72M | $95.66M | $112.86M | $28.16M | $87.39M | $21.07M | $63.90M | $71.44M | $72.86M | $71.97M | $63.53M | $69.49M | $102.65M | $114.01M | $887.00K | $1.01M |
| Operating Cash Flow | $-21.82M | $-24.55M | $-13.99M | $-10.41M | $-9.34M | $-9.20M | $-7.37M | $-7.55M | $-6.67M | $-5.88M | $-7.49M | $-7.53M | $-7.92M | $-12.20M | $-10.78M | $-11.21M | $-9.86M | $-11.22M | $-12.20M | $-8.92M |
| Capital Expenditure | $-179.00K | $-62.00K | $-274.00K | $- | $-164.00K | $- | $- | $- | $- | $- | $-100.00K | $- | $-9.00K | $-293.00K | $-31.00K | $- | $-1.00K | $-5.00K | $- | $-58.00K |
| Free Cash Flow | $-21.99M | $-24.61M | $-14.26M | $-10.41M | $-9.51M | $-9.20M | $-7.37M | $-7.55M | $-6.67M | $-5.88M | $-7.59M | $-7.53M | $-7.93M | $-12.49M | $-10.81M | $-11.21M | $-9.86M | $-11.23M | $-12.20M | $-8.98M |
Larimar Therapeutics Dividends
Explore Larimar Therapeutics's dividend history, including dividend yield, payout ratio, and historical payments.
Larimar Therapeutics News
Read the latest news about Larimar Therapeutics, including recent articles, headlines, and updates.
Larimar Therapeutics Provides Nomlabofusp Development Update and Reports Fourth Quarter and Full Year 2024 Financial Results
BALA CYNWYD, Pa., March 24, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2024 operating and financial results.
Larimar Therapeutics to Present at the Leerink Partners Global Healthcare Conference
BALA CYNWYD, Pa., March 03, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Healthcare Conference, taking place in Miami Beach, FL from March 10 – 12, 2025.
Larimar Therapeutics Announces Dosing of Adolescents in Nomlabofusp Pediatric Pharmacokinetic Run-In Study for Patients with Friedreich's Ataxia
BALA CYNWYD, Pa., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that dosing of adolescents 12-17 years old has started in the Company's pediatric PK run-in study for patients with Friedreich's ataxia (FA).
Larimar Therapeutics: Positive Friedreich's Ataxia Data Can Only Get Better
Larimar Therapeutics, Inc. reported initial positive data from phase 2 long-term OLE study using nomlabofusp for treatment of patients with Friedreich's Ataxia; Increase of tissue FXN protein levels from 15% to 30%. The global Friedreich's Ataxia market size is projected to reach $2.06 billion by 2030. Additional data using higher 50 mg dose of nomlabofusp to treat patients with Friedreich's Ataxia expected in mid-2025.
What's Going On With Larimar Therapeutics Stock On Tuesday?
On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich's Ataxia.
Market 'misinterpreting' Larimar data, selloff 'overdone,' says Citi
Citi analyst Samantha Semenkow notes Larimar Therapeutics announced initial data from the ongoing long-term Open Label Extension study evaluating daily subcutaneous injections of 25 mg of nomlabofusp and calls the market's negative reaction to the disclosure "at odds with what we view as a very positive dataset." The firm, which believes the market is "misinterpreting the two reported SAEs that led to discontinuations as a signal of a broader safety issue," believes the longer-term safety data reported today begin to confirm that nomlabofusp is safe and tolerable for chronic dosing. The firm, which views today's selloff as "overdone," would be "buyers on the dip" and maintains a Buy rating and $14 price target on Larimar shares.
Why Is Larimar Therapeutics Stock Trading Lower On Monday?
On Monday, Larimar Therapeutics, Inc. LRMR released initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with Friedreich's Ataxia.
Larimar Therapeutics Announces Positive Initial Data from Ongoing Long-term Open Label Extension Study & Progress Across Nomlabofusp Program for Friedreich's Ataxia
BALA CYNWYD, Pa., Dec. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive initial data from the ongoing long-term OLE study evaluating daily subcutaneous injections of 25 mg of nomlabofusp self-administered or administered by a caregiver in participants with FA. The Company also provided a nomlabofusp development program update.
Wall Street Analysts Think Larimar (LRMR) Could Surge 192.89%: Read This Before Placing a Bet
The mean of analysts' price targets for Larimar (LRMR) points to a 192.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.
Larimar Therapeutics Reports Third Quarter 2024 Operating and Financial Results
BALA CYNWYD, Pa., Oct. 30, 2024 (GLOBE NEWSWIRE) -- October 30, 2024 – Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter 2024 operating and financial results.
Larimar Therapeutics' Friedreich's Ataxia Approach Could Have Considerable Upside Potential
Larimar Therapeutics' CTI-1601, a potential first-in-class treatment for Friedreich's ataxia, shows promise in modifying disease progression and restoring mitochondrial function. The company has a solid cash runway, sufficient liquidity, and trades at reasonable valuations compared to its upside potential. LRMR's favorable Phase 1/2 trial results bolster CTI-1601's approval odds, with a potential Biologics License Application submission by 2H2025.
Larimar Therapeutics Announces Three Poster Presentations at the Upcoming International Congress for Ataxia Research
BALA CYNWYD, Pa., Sept. 19, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that data from the Company's nomlabofusp Phase 1 studies and Phase 2 dose exploration study, some of which has been previously disclosed, will be presented at the annual International Congress for Ataxia Research (ICAR) being held November 12-15, 2024 in London, U.K. Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich's ataxia by delivering frataxin to mitochondria.
Larimar Therapeutics Selected by FDA to Participate in START Pilot Program for Nomlabofusp in Friedreich's Ataxia
BALA CYNWYD, Pa., May 30, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that the United States Food and Drug Administration (FDA) has selected nomlabofusp to participate in the Support for Clinical Trials Advancing Rare Disease Therapeutics (START) pilot program. Nomlabofusp is a novel protein replacement therapy designed to address the root cause of Friedreich's ataxia (FA) by delivering frataxin to mitochondria. START selection was based on demonstrated development program readiness, including the potential of nomlabofusp to address the serious and unmet medical needs in a rare neurodegenerative condition, alignment of chemistry, manufacturing, and controls (CMC) development timelines with clinical development plans, and a proposed communications plan where enhanced communication could accelerate pivotal study initiation and path to potential Biologics License Application (BLA) submission.
Larimar Therapeutics Announces FDA has Removed Partial Clinical Hold for Nomlabofusp Program in Friedreich's Ataxia
BALA CYNWYD, Pa., May 20, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (Larimar) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the U.S. FDA has removed the partial clinical hold previously placed on the company's nomlabofusp (CTI-1601) clinical program. Nomlabofusp is currently in development for the treatment of patients with Friedreich's Ataxia (FA). Nomlabofusp is a novel protein replacement therapy designed to address the root cause of FA by delivering frataxin to mitochondria. The FDA removed the partial clinical hold after a review of data from the Company's recently completed four-week, placebo-controlled Phase 2 dose exploration study. The review included data from both the 25 mg and 50 mg cohorts in patients who received daily dosing of nomlabofusp for 14 days followed by every other day dosing until day 28.
Larimar Therapeutics Reports First Quarter 2024 Operating and Financial Results
BALA CYNWYD, Pa., May 09, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its first quarter 2024 operating and financial results.
Larimar Therapeutics Reports Fourth Quarter and Full Year 2023 Operating and Financial Results and Provides Update on Nomlabofusp Development
BALA CYNWYD, Pa., March 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its fourth quarter and full year 2023 operating and financial results.
Larimar Therapeutics Announces the Dosing of the First Patient in Long-term Open Label Extension Study for Nomlabofusp in Patients with Friedreich's Ataxia
BALA CYNWYD, Pa., March 11, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced dosing of the first patient in an open label extension (OLE) study evaluating 25 mg daily subcutaneous injections of nomlabofusp in participants with Friedreich's ataxia (FA). Nomlabofusp (CTI-1601) is a novel protein replacement therapy designed to address the root cause of Friedreich's ataxia (FA) by delivering frataxin to mitochondria.
Larimar Therapeutics to Present at the Leerink Partners Global Biopharma Conference
BALA CYNWYD, Pa., March 06, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that members of the company's management team will present and participate in 1x1 investor meetings at the Leerink Partners Global Biopharma Conference, taking place in Miami Beach, FL from March 11 – 13, 2024.
Larimar Therapeutics Announces Closing of Underwritten Public Offering of Common Stock and Exercise in Full of the Underwriters' Option to Purchase Additional Shares
BALA CYNWYD, Pa., Feb. 16, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the closing of its previously announced underwritten public offering of 19,736,842 shares of its common stock, which includes the exercise in full of the underwriters' option to purchase 2,574,370 additional shares, at the public offering price of $8.74 per share, the closing price of its common stock on February 13, 2024. The aggregate gross proceeds to Larimar from this offering, before deducting underwriting discounts and commissions and estimated offering expenses, were approximately $172.5 million.
Larimar Therapeutics Announces Pricing of Underwritten Public Offering of Common Stock
BALA CYNWYD, Pa., Feb. 14, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the pricing of its previously announced underwritten public offering of 17,162,472 shares of its common stock at a price to the public of $8.74 per share, the closing price of its common stock on February 13, 2024, for gross proceeds of approximately $150.0 million, before deducting underwriting discounts and commissions and other offering expenses. In addition, Larimar has granted the underwriters a 30-day option to purchase up to an additional 2,574,370 shares of its common stock at the public offering price, less underwriting discounts and commissions. All shares of common stock are being offered by Larimar. The offering is expected to close on or about February 16, 2024, subject to the satisfaction of customary closing conditions.
Larimar Therapeutics Announces Proposed Underwritten Public Offering
BALA CYNWYD, Pa., Feb. 13, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced that it has commenced an underwritten public offering of shares of its common stock and, in lieu of shares of common stock to certain investors that so choose, pre-funded warrants to purchase shares of common stock. In addition, Larimar expects to grant the underwriters a 30-day option to purchase up to an additional 15% of the securities to be sold in the proposed offering at the public offering price, less underwriting discounts and commissions. All shares of common stock and pre-funded warrants in the proposed offering are to be sold by Larimar. The proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or the actual size or terms of the proposed offering.
Larimar Therapeutics Reports Positive Top-line Data from Phase 2 Dose Exploration Study from 25 mg and 50 mg Cohorts of Nomlabofusp in Patients with Friedreich's Ataxia
BALA CYNWYD, Pa., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced positive top-line data and successful completion of its four-week, placebo-controlled Phase 2 dose exploration study of nomlabofusp (CTI-1601) in participants with Friedreich's ataxia (FA). Nomlabofusp was generally well tolerated and demonstrated dose dependent increases in frataxin (FXN) levels in all evaluated tissues (skin and buccal cells) after daily dosing of 14 days followed by every other day dosing until day 28 in the 25 mg and 50 mg cohorts. Participants in the 25 mg (n=13) and 50 mg (n=15) cohorts were randomized 2:1 to receive subcutaneous injections of nomlabofusp or placebo.
Larimar Therapeutics Reports Third Quarter 2023 Operating and Financial Results
BALA CYNWYD, Pa., Nov. 14, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today reported its third quarter operating and financial results.
Larimar Therapeutics Appoints Dr. Jeffery W. Sherman to its Board of Directors
BALA CYNWYD, Pa., Oct. 03, 2023 (GLOBE NEWSWIRE) -- Larimar Therapeutics, Inc. (“Larimar”) (Nasdaq: LRMR), a clinical-stage biotechnology company focused on developing treatments for complex rare diseases, today announced the appointment of Jeffrey W. Sherman, M.D., F.A.C.P. to the Company's Board of Directors, effective today. Dr. Sherman, currently Executive Vice President, Chief Medical Officer (CMO) at Horizon Therapeutics Public Limited Company, has over 20 years of executive experience in regulatory and clinical strategy.
Similar Companies
Related Metrics
Explore detailed financial metrics and analysis for LRMR.